Bohiri Y

References (3)

Title : Rivastigmine augmentation in the management of chronic schizophrenia with comorbid dementia: an open-label study investigating effects on cognition, behaviour and activities of daily living - Mendelsohn_2004_Int.Clin.Psychopharmacol_19_319
Author(s) : Mendelsohn E , Rosenthal M , Bohiri Y , Werber E , Kotler M , Strous RD
Ref : Int Clin Psychopharmacol , 19 :319 , 2004
Abstract :
PubMedSearch : Mendelsohn_2004_Int.Clin.Psychopharmacol_19_319
PubMedID: 15486516

Title : Rivastigmine augmentation in the management of chronic schizophrenia with comorbid dementia: an open-label study investigating effects on cognition, behaviour and activities of daily living - Mendelsohn_2004_Int.Clin.Psychopharmacol_19_319
Author(s) : Mendelsohn E , Rosenthal M , Bohiri Y , Werber E , Kotler M , Strous RD
Ref : Int Clin Psychopharmacol , 19 :319 , 2004
Abstract :
PubMedSearch : Mendelsohn_2004_Int.Clin.Psychopharmacol_19_319
PubMedID: 15486516

Title : Rivastigmine augmentation in the management of chronic schizophrenia with comorbid dementia: an open-label study investigating effects on cognition, behaviour and activities of daily living - Mendelsohn_2004_Int.Clin.Psychopharmacol_19_319
Author(s) : Mendelsohn E , Rosenthal M , Bohiri Y , Werber E , Kotler M , Strous RD
Ref : Int Clin Psychopharmacol , 19 :319 , 2004
Abstract :
PubMedSearch : Mendelsohn_2004_Int.Clin.Psychopharmacol_19_319
PubMedID: 15486516